Association between expression of X-linked inhibitor of apoptosis protein and the clinical outcome in a BRAFV600E-prevalent papillary thyroid cancer population

Thyroid

Volumn 24, Issue 4, 2014, Pages 689-694

  Yim, Ji Hye ^a   Kim, Won Gu ^a   Jeon, Min Ji ^a   Han, Ji Min ^a   Kim, Tae Yong ^a   Yoon, Jong Ho ^a   Hong, Suck Joon ^a   Song, Dong Eun ^a   Gong, Gyungyub ^a   Shong, Young Kee ^a   Kim, Won Bae ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DNA; IODINE 131; MONOCLONAL ANTIBODY; X LINKED INHIBITOR OF APOPTOSIS; BRAF PROTEIN, HUMAN; RADIOACTIVE IODINE; TUMOR MARKER; XIAP PROTEIN, HUMAN;

ABLATION THERAPY; ADULT; ARTICLE; ASIAN; BRAF V600E GENE; CANCER RECURRENCE; CANCER SURVIVAL; CERVICAL LYMPH NODE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ONCOGENE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; WILD TYPE; AMINO ACID SUBSTITUTION; CARCINOMA, PAPILLARY; GENE FREQUENCY; GENETICS; METABOLISM; MIDDLE AGED; MISSENSE MUTATION; MULTIMODALITY CANCER THERAPY; PROGNOSIS; SOUTH KOREA; THYROID NEOPLASMS;

ADULT; AMINO ACID SUBSTITUTION; BIOMARKERS, TUMOR; CARCINOMA, PAPILLARY; COMBINED MODALITY THERAPY; FEMALE; GENE FREQUENCY; HUMANS; IMMUNOHISTOCHEMISTRY; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; MUTATION, MISSENSE; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; REPUBLIC OF KOREA; THYROID NEOPLASMS; THYROIDECTOMY; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84898465257     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2012.0585     Document Type: Article

References (34)

1. Davies L, Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295:2164-2167.
2. Mazzaferri EL, Jhiang SM 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418-428.
3. Sawka AM, Goldstein DP, Brierley JD, Tsang RW, Rotstein L, Ezzat S, Straus S, George SR, Abbey S, Rodin G, O'Brien MA, Gafni A, Thabane L, Goguen J, Naeem A, Magalhaes L 2009 The impact of thyroid cancer and post-surgical radioactive iodine treatment on the lives of thyroid cancer survivors: A qualitative study. PLoS ONE 4:e4191.
4. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW 2005 BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373-6379
5. Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, Materazzi G, Elisei R, Santoro M, Miccoli P, Basolo F 2007 Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 92:4085-4090
6. Xing M 2007 BRAF mutation in papillary thyroid cancer: Pathogenic role, molecular bases, and clinical implications. Endocr Rev 28:742-762
7. Hunter AM, LaCasse EC, Korneluk RG 2007 The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 12:1543
8. Holcik M, Korneluk RG 2001 XIAP, the guardian angel. Nat Rev Mol Cell Biol 2:550-556
9. Kashkar H 2010 X-linked inhibitor of apoptosis: A chemoresistance factor or a hollow promise. Clin Cancer Res 16:4496-4502
10. Srinivasula SM, Ashwell JD 2008 IAPs: What's in a namé Mol Cell 30:123-135
11. Xiao GQ, Unger PD, Burstein DE 2007 Immunohistochemical detection of X-linked inhibitor of apoptosis (XIAP) in neoplastic and other thyroid disorders. Ann Diagn Pathol 11:235-240
12. Yim JH, Yoon JH, Kim SA, Kim WG, Jeon MJ, Han JM, Sung TY, Kim TY, Kim WB, Hong SJ, Shong YK, Gong G 2011 Expression of X-linked inhibitor of apoptosis protein in neoplastic thyroid disorder. J Korean Med Sci 26:1191-1195
13. Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, Lee S, Kim SY, Kim SC, Hong SJ, Shong YK 2006 The BRAF mutation is useful for prediction of clinical recurrence in lowrisk patients with conventional papillary thyroid carcinoma. Clin Endocrinol 65:364-368
14. Han JM, Bae Kim W, Yim JH, Kim WG, Kim TY, Ryu JS, Gong G, Sung TY, Yoon JH, Hong SJ, Kim EY, Shong YK 2012 Long-term clinical outcome of differentiated thyroid cancer patients with undetectable stimulated thyroglobulin level one year after initial treatment. Thyroid 22:784-790
15. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M (Eds) 2002 AJCC Cancer Staging Manual, 6th ed. Springer, New York.
16. Riedl SJ, Renatus M, Schwarzenbacher R, Zhou Q, Sun C, Fesik SW, Liddington RC, Salvesen GS 2001 Structural basis for the inhibition of caspase-3 by XIAP. Cell 104:791-800
17. Chai J, Shiozaki E, Srinivasula SM, Wu Q, Datta P, Alnemri ES, Shi Y 2001 Structural basis of caspase-7 inhibition by XIAP. Cell 104:769-780
18. Shiozaki EN, Chai J, Rigotti DJ, Riedl SJ, Li P, Srinivasula SM, Alnemri ES, Fairman R, Shi Y 2003 Mechanism of XIAPmediated inhibition of caspase-9. Mol Cell 11:519-527
19. Tamm I, Kornblau SM, Segall H, Krajewski S, Welsh K, Kitada S, Scudiero DA, Tudor G, Qui YH, Monks A, Andreeff M, Reed JC 2000 Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 6:1796-1803
20. Liu SS, Tsang BK, Cheung AN, Xue WC, Cheng DK, Ng TY, Wong LC, Ngan HY 2001 Anti-apoptotic proteins, apoptotic and proliferative parameters and their prognostic significance in cervical carcinoma. Eur J Cancer 37:1104-1110
21. Krajewska M, Kim H, Kim C, Kang H, Welsh K, Matsuzawa S, Tsukamoto M, Thomas RG, Assa-Munt N, Piao Z, Suzuki K, Perucho M, Krajewski S, Reed JC 2005 Analysis of apoptosis protein expression in early-stage colorectal cancer suggests opportunities for new prognostic biomarkers. Clinical Cancer Res 11:5451-5461
22. Gu LQ, Li FY, Zhao L, Liu Y, Chu Q, Zang XX, Liu JM, Ning G, Zhao YJ 2010 Association of XIAP and P2X7 receptor expression with lymph node metastasis in papillary thyroid carcinoma. Endocrine 38:276-282
23. Gu LQ, Li FY, Zhao L, Liu Y, Zang XX, Wang TX, Chen HP, Ning G, Zhao YJ 2009 BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma. Thyroid 19:347-354
24. Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ, Kim KW, Hahn SK, Youn YK, Kim KH, Cho BY, Park do J 2012 The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: A meta-analysis. Cancer 118:1764-1773
25. Ciampi R, Nikiforov YE 2007 RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 148:936-941
26. Sumimoto H, Imabayashi F, Iwata T, Kawakami Y 2006 The BRAF-MAPK signaling pathway is essential for cancerimmune evasion in human melanoma cells. J Exp Med 203: 1651-1656
27. Song G, Ouyang G, Bao S 2005 The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 9:59-71
28. Wennstrom S, Downward J 1999 Role of phosphoinositide 3- kinase in activation of Ras and mitogen-activated protein kinase by epidermal growth factor. Mol Cell Biol 19:4279
29. McCubrey JA, Lee JT, Steelman LS, Blalock WL, Moye PW, Chang F, Pearce M, Shelton JG, White MK, Franklin RA, Pohnert SC 2001 Interactions between the PI3K and Raf signaling pathways can result in the transformation of hematopoietic cells. Cancer Detect Prev 25:375-393
30. Sheng H, Shao J, DuBois RN 2001 Akt/PKB activity is required for Ha-Ras-mediated transformation of intestinal epithelial cells. J Biol Chem 276:14498-14504
31. Carter BZ, Milella M, Tsao T, McQueen T, Schober WD, Hu W, Dean NM, Steelman L, McCubrey JA, Andreeff M 2003 Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia. Leukemia 17:2081-2089
32. Abkhezr M, Keramati AR, Ostad SN, Davoodi J, Ghahremani MH 2010 The time course of Akt and ERK activation on XIAP expression in HEK 293 cell line. Mol Biol Rep 37:2037-2042
33. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, Moritz RL, Simpson RJ, Vaux DL 2000 Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102:43-53
34. Du C, Fang M, Li Y, Li L, Wang X 2000 Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102:33-42.